These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

235 related articles for article (PubMed ID: 25586713)

  • 1. Extending the diabetic retinopathy screening interval beyond 1 year: systematic review.
    Taylor-Phillips S; Mistry H; Leslie R; Todkill D; Tsertsvadze A; Connock M; Clarke A
    Br J Ophthalmol; 2016 Jan; 100(1):105-14. PubMed ID: 25586713
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Modelling the cost-effectiveness of adopting risk-stratified approaches to extended screening intervals in the national diabetic retinopathy screening programme in Scotland.
    Scotland G; McKeigue P; Philip S; Leese GP; Olson JA; Looker HC; Colhoun HM; Javanbakht M
    Diabet Med; 2016 Jul; 33(7):886-95. PubMed ID: 27040994
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Optimal strategies for identifying kidney disease in diabetes: properties of screening tests, progression of renal dysfunction and impact of treatment - systematic review and modelling of progression and cost-effectiveness.
    Farmer AJ; Stevens R; Hirst J; Lung T; Oke J; Clarke P; Glasziou P; Neil A; Dunger D; M Colhoun H; Pugh C; Wong G; Perera R; Shine B
    Health Technol Assess; 2014 Feb; 18(14):1-128. PubMed ID: 24576414
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cost-effectiveness of biennial screening for diabetes related retinopathy in people with type 1 and type 2 diabetes compared to annual screening.
    Thomas RL; Winfield TG; Prettyjohns M; Dunstan FD; Cheung WY; Anderson PM; Peter R; Luzio SD; Owens DR
    Eur J Health Econ; 2020 Sep; 21(7):993-1002. PubMed ID: 32385543
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A decade-long telemedicine screening program for diabetic retinopathy in the north-east of Italy.
    Vujosevic S; Pucci P; Casciano M; Daniele A; Bini S; Berton M; Cavarzeran F; Avogaro A; Lapolla A; Midena E
    J Diabetes Complications; 2017 Aug; 31(8):1348-1353. PubMed ID: 28551296
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cost-effectiveness of Autonomous Point-of-Care Diabetic Retinopathy Screening for Pediatric Patients With Diabetes.
    Wolf RM; Channa R; Abramoff MD; Lehmann HP
    JAMA Ophthalmol; 2020 Oct; 138(10):1063-1069. PubMed ID: 32880616
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Diabetic retinopathy screening: a systematic review of the economic evidence.
    Jones S; Edwards RT
    Diabet Med; 2010 Mar; 27(3):249-56. PubMed ID: 20536486
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Use of personalised risk-based screening schedules to optimise workload and sojourn time in screening programmes for diabetic retinopathy: A retrospective cohort study.
    Ochs A; McGurnaghan S; Black MW; Leese GP; Philip S; Sattar N; Styles C; Wild SH; McKeigue PM; Colhoun HM;
    PLoS Med; 2019 Oct; 16(10):e1002945. PubMed ID: 31622334
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evaluation of telemedicine for screening of diabetic retinopathy in the Veterans Health Administration.
    Kirkizlar E; Serban N; Sisson JA; Swann JL; Barnes CS; Williams MD
    Ophthalmology; 2013 Dec; 120(12):2604-2610. PubMed ID: 24084501
    [TBL] [Abstract][Full Text] [Related]  

  • 10. First Incidence and Progression Study for Diabetic Retinopathy in Portugal, the RETINODIAB Study: Evaluation of the Screening Program for Lisbon Region.
    Dutra Medeiros M; Mesquita E; Gardete-Correia L; Moita J; Genro V; Papoila AL; Amaral-Turkman A; Raposo JF
    Ophthalmology; 2015 Dec; 122(12):2473-81. PubMed ID: 26383994
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Individualised screening for diabetic retinopathy: the ISDR study-rationale, design and methodology for a randomised controlled trial comparing annual and individualised risk-based variable-interval screening.
    Broadbent DM; Sampson CJ; Wang A; Howard L; Williams AE; Howlin SU; Appelbe D; Moitt T; Cheyne CP; Rahni MM; Kelly J; Collins J; García-Fiñana M; Stratton IM; James M; Harding SP;
    BMJ Open; 2019 Jun; 9(6):e025788. PubMed ID: 31213445
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A systematic review of diabetic retinopathy screening intervals.
    Drinkwater JJ; Kalantary A; Turner AW
    Acta Ophthalmol; 2024 Jun; 102(4):e473-e484. PubMed ID: 37915115
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Retinopathy screening in individuals with type 2 diabetes: who, how, how often, and at what cost--an epidemiologic review.
    Swanson M
    Optometry; 2005 Nov; 76(11):636-46. PubMed ID: 16298316
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Safety and cost-effectiveness of individualised screening for diabetic retinopathy: the ISDR open-label, equivalence RCT.
    Broadbent DM; Wang A; Cheyne CP; James M; Lathe J; Stratton IM; Roberts J; Moitt T; Vora JP; Gabbay M; García-Fiñana M; Harding SP;
    Diabetologia; 2021 Jan; 64(1):56-69. PubMed ID: 33146763
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Screening intervals for diabetic retinopathy and incidence of visual loss: a systematic review.
    Echouffo-Tcheugui JB; Ali MK; Roglic G; Hayward RA; Narayan KM
    Diabet Med; 2013 Nov; 30(11):1272-92. PubMed ID: 23819487
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cost-effectiveness of diabetic retinopathy screening for newly diagnosed type 2 diabetic patients: A nationwide population-based propensity score-matched cohort study.
    Chung YC; Kao YW; Huang YC; Chen PE; Liao SC; Liu CK; Chen M
    Asia Pac J Ophthalmol (Phila); 2024; 13(3):100071. PubMed ID: 38768659
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Individualised risk assessment for diabetic retinopathy and optimisation of screening intervals: a scientific approach to reducing healthcare costs.
    Lund SH; Aspelund T; Kirby P; Russell G; Einarsson S; Palsson O; Stefánsson E
    Br J Ophthalmol; 2016 May; 100(5):683-7. PubMed ID: 26377413
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Predicted impact of extending the screening interval for diabetic retinopathy: the Scottish Diabetic Retinopathy Screening programme.
    Looker HC; Nyangoma SO; Cromie DT; Olson JA; Leese GP; Philip S; Black MW; Doig J; Lee N; Briggs A; Hothersall EJ; Morris AD; Lindsay RS; McKnight JA; Pearson DW; Sattar NA; Wild SH; McKeigue P; Colhoun HM;
    Diabetologia; 2013 Aug; 56(8):1716-25. PubMed ID: 23689796
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cost-effectiveness of a National Telemedicine Diabetic Retinopathy Screening Program in Singapore.
    Nguyen HV; Tan GS; Tapp RJ; Mital S; Ting DS; Wong HT; Tan CS; Laude A; Tai ES; Tan NC; Finkelstein EA; Wong TY; Lamoureux EL
    Ophthalmology; 2016 Dec; 123(12):2571-2580. PubMed ID: 27726962
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Systematic review on urine albumin testing for early detection of diabetic complications.
    Newman DJ; Mattock MB; Dawnay AB; Kerry S; McGuire A; Yaqoob M; Hitman GA; Hawke C
    Health Technol Assess; 2005 Aug; 9(30):iii-vi, xiii-163. PubMed ID: 16095545
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.